On 13 November 2025, Merck Sharp & Dohme LLC initiated a study is to learn if people who receive patritumab deruxtecan (also ...

Theravance Biopharma, Inc. (NASDAQ: TBPH) today announced that it will host a virtual key opinion leader (KOL) investor event on Monday, December 8, 2025 at 10:30 AM ET. To register, click here.

The leading Familial Chylomicronemia Syndrome Companies such as Ionis Pharmaceuticals, Pfizer, Arrowhead Pharmaceuticals, ...

Medica 2025 is one of the most influential international meeting points for professionals from healthcare, medical technology ...

Long COVID study finds vitamin B3 derivative safely elevates NAD⁺; while cognitive gains were limited, fatigue and sleep ...

Alterity Therapeutics ( ($AU:ATH) ) has provided an update. Alterity Therapeutics announced the results of its 2025 Annual General Meeting, ...

Breast Cancer Canada has released its 2025 Annual Progress Report, offering a comprehensive overview of breast cancer care in Canada. The report highlights advances in treatment, screening, and policy ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced topline results from the pivotal ...

This story is part of your SHN+ subscription Senior living resident satisfaction scores are on the rise, but to keep residents and their families happy in ...

Drs Joseph Mikhael and Sigurdur Y. Kristinsson discuss whether it is time to screen for multiple myeloma and what we can ...

Azenta ranks at the bottom for Revenue Growth and Gross Profit, with negative percentages. It also has the lowest Return on ...

Dear Stockholders, Stakeholders, Strategic and Potential Strategic Partners and Other Interested Parties : As we prepare to end 2025, we would like to provide you with this open letter summarizing our ...